EA200900531A1 - Фармацевтические составы - Google Patents

Фармацевтические составы

Info

Publication number
EA200900531A1
EA200900531A1 EA200900531A EA200900531A EA200900531A1 EA 200900531 A1 EA200900531 A1 EA 200900531A1 EA 200900531 A EA200900531 A EA 200900531A EA 200900531 A EA200900531 A EA 200900531A EA 200900531 A1 EA200900531 A1 EA 200900531A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
active substance
composition
acid salt
polymer matrix
Prior art date
Application number
EA200900531A
Other languages
English (en)
Inventor
Йи Гао
Р. Йю Тцучи
Деннис Й. Ли
Николь Нгуен
Хауилианг Ву
Original Assignee
Эббот Лаборейторис
Форнэр Лаборейторис Айерлэнд Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббот Лаборейторис, Форнэр Лаборейторис Айерлэнд Лтд. filed Critical Эббот Лаборейторис
Publication of EA200900531A1 publication Critical patent/EA200900531A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение предлагает состав с модифицированным высвобождением, включающий активное вещество с гидрофильной полимерной матрицей, где активным веществом является соль фенофибриновой кислоты и где скорость высвобождения состава при растворении in vitro в основном не зависит от ионной силы растворяющей среды.
EA200900531A 2006-10-12 2007-10-12 Фармацевтические составы EA200900531A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82925506P 2006-10-12 2006-10-12
PCT/US2007/081267 WO2008046052A1 (en) 2006-10-12 2007-10-12 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
EA200900531A1 true EA200900531A1 (ru) 2009-12-30

Family

ID=38961056

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900531A EA200900531A1 (ru) 2006-10-12 2007-10-12 Фармацевтические составы

Country Status (14)

Country Link
EP (1) EP2081563A1 (ru)
JP (1) JP2010506855A (ru)
KR (1) KR20090119959A (ru)
CN (1) CN101677981A (ru)
AU (1) AU2007307641A1 (ru)
CA (1) CA2672686A1 (ru)
CO (1) CO6160302A2 (ru)
EA (1) EA200900531A1 (ru)
EC (1) ECSP099251A (ru)
IL (1) IL198160A0 (ru)
MX (1) MX2009003815A (ru)
SG (1) SG175570A1 (ru)
WO (1) WO2008046052A1 (ru)
ZA (1) ZA200902488B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5553452B2 (ja) * 2008-05-30 2014-07-16 ユセベ ファルマ ソシエテ アノニム ブリバラセタムを含む医薬組成物
CN102304103A (zh) * 2011-06-03 2012-01-04 郑州泰基鸿诺药物科技有限公司 一种非诺贝特酸盐、制备方法、药物组合物及应用
CN102659570B (zh) * 2012-05-17 2014-05-28 安润医药科技（苏州）有限公司 二氟非诺贝特酸及其在药学上可接受的盐，以及它们的制备方法和应用
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CN107496397A (zh) * 2016-06-14 2017-12-22 重庆安格龙翔医药科技有限公司 一种二甲双胍与非诺贝酸的复合物及其制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1832285A1 (en) * 2002-12-17 2007-09-12 Abbott GmbH & Co. KG Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
DE60313359T2 (de) * 2002-12-17 2008-01-03 Abbott Gmbh & Co. Kg Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
CN101217944A (zh) * 2005-04-08 2008-07-09 艾博特公司 包含非诺贝酸和/或其盐的口服药物制剂

Also Published As

Publication number Publication date
JP2010506855A (ja) 2010-03-04
CN101677981A (zh) 2010-03-24
ZA200902488B (en) 2010-10-27
ECSP099251A (es) 2009-06-30
SG175570A1 (en) 2011-11-28
MX2009003815A (es) 2009-09-07
EP2081563A1 (en) 2009-07-29
WO2008046052A1 (en) 2008-04-17
IL198160A0 (en) 2009-12-24
CA2672686A1 (en) 2008-04-17
KR20090119959A (ko) 2009-11-23
AU2007307641A1 (en) 2008-04-17
CO6160302A2 (es) 2010-05-20

Similar Documents

Publication Publication Date Title
Han et al. Advances in hemostatic hydrogels that can adhere to wet surfaces
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
PL2148703T3 (pl) Nowy środek umożliwiający wysalanie substancji czynnych w opatrunkach zawierających co najmniej jedną substancję tłuszczową
CN115038465A (zh) 炎症反应性抗炎水凝胶
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
Liu et al. Biological glue from only lipoic acid for scarless wound healing by anti-inflammation and TGF-β regulation
BR112013016772B8 (pt) compostos, uso do composto e composição farmacêutica
CA2784827C (en) Composition of dexibuprofen transdermal hydrogel
CY1113207T1 (el) Στερεη μορφη δοσολογιας που περιεχει αναστολεα αντλιας πρωτονιων και εναιωρημα που παρασκευαζεται απο αυτη
EA200901365A1 (ru) Стабилизированная фармацевтическая композиция, содержащая прегабалин
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
EA201071409A1 (ru) Новые соли (4-{[(5-{[(3-хлорфенил)метил]окси}-2-метилфенил)карбонил]амино}-3-метилфенил)уксусной кислоты
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
EA200900531A1 (ru) Фармацевтические составы
ATE543507T1 (de) Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
MX2009012742A (es) Ingrediente activo novedoso en cicatrizacion y uso del mismo.
TR201820076T4 (tr) İlaç kombinasyonlarının salımı.
NI201100119A (es) Composición de liberación pulsatil de sildenafil y proceso para prepararla.
TR201906158T4 (tr) Etken Maddeler ile Farmasötik-Teknolojik Yardımcı Maddeler Arasındaki Etkileşimleri Engellemek Amacıyla Kullanılan Farmasötik Preparatlar İçin Ayırıcı Katmanlar.
EA201070806A1 (ru) Состав медленного высвобождения на основе ассоциации гликогена и альгината
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
EA201190050A1 (ru) Композиция кветиапина
ATE438385T1 (de) Pharmazeutische zusammensetzung
EA200701228A1 (ru) Стабильные композиции фенофибрата с эфирами жирных кислот